Pfizer Inc. today announced positive topline results from the progression-free survival (PFS) analysis of the Phase 3 BREAKWATER study of BRAFTOVI® (encorafenib) in combination with cetuximab ...

Pfizer Inc. (NYSE: PFE) today announced positive topline results from the progression-free survival (PFS) analysis of the Phase 3 BREAKWATER study of ...

Children’s Healthcare of Atlanta’s heart clinics treat about 200 children a year. This includes Audrey Koch, a Roswell teen with a heart condition called Long QT syndrome.

Although uncommon, long QT syndrome can happen with Kisqali treatment. The QT interval is part of your heart’s natural rhythm. In studies, Kisqali caused the QT interval to lengthen. This is ...

Background and objective: Prolonged QTc interval on admission and a higher risk of death in SARS-CoV-2 patients have been reported. The long-term clinical impact of prolonged QTc interval is unknown.

Design A large-scale cohort study with retrospective analysis of baseline and on-therapy QT interval corrected using Bazett and Fridericia formulas. Setting A multicentre study involving eight ...

QTc Interval Prolongation: XOLREMDI causes concentration-dependent QTc prolongation. QTc prolongation may occur when XOLREMDI is taken with concomitant medications that increase XOLREMDI exposure ...

However, the relationship between IGFs and IGFBP-3 with the QTc interval in humans, is unknown. Objectives: To examine the association of IGFs and IGFBP-3 with QTc interval in an older age ...

The project involves extracting and analyzing genetic variants from the ClinVar database and processing ECG signals to calculate QT intervals. Genotype Data Analysis The main outcome of this part was ...

Everyone is encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1 ...

Current clinical tools rely on known cardiovascular risk elements, but they often do not account for complex interactions ...

95 percent confidence interval, 0.51 to 0.84; one-sided P = 0.0002). Twenty-nine and 34 percent of patients in the TACE with lenvatinib plus pembrolizumab and TACE plus placebo groups died ...